Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     
  • Bitcoin GBP

    51,880.48
    +1,770.78 (+3.53%)
     
  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

BUZZ-GSK dividend looks safe post-Brexit, even with new CEO

** Jefferies analysts upgrade GlaxoSmithKline (Other OTC: GLAXF - news) to buy from hold with 2,000p PT on growing confidence in drugmaker's 4.9% dividend yield. Stock up 1.5% at 1,670p

** Say fears of a dividend cut linked to the appointment of a new CEO are "overdone" and estimate 2015 payout ratio of 132% will fall to around 88% in 2016 and 63% in 2020, assuming continued flat divi

** GBP weakness post Brexit makes divi more secure, allaying investor concerns about group's ability to pay a promised 80p/share this year and next, and maintaining payouts beyond 2017

(RM (LSE: RM.L - news) :ben.hirschler.thomsonreuters.com@reuters.net)